Posted by Michael Wonder on 28 May 2021
Verrica Pharmaceuticals announces extension of FDA review period of its NDA for VP-102 for the treatment of molluscum contagiosum
28 May 2021 - Prescription Drug User Fee Act goal date extended by three months to 23 September 2021.
Verrica Pharmaceuticals today announced that the U.S. FDA has extended the review period for the new drug application for VP-102 for the treatment of molluscum contagiosum.
